T-reg 转录密码签名识别了对检查点抑制剂的反应
María Del Mar Noblejas-López1,2,3, Elena García-Gil1, Pedro Pérez-Segura4
1Translational Research Unit, Translational Oncology Laboratory, Albacete University Hospital, 02008, Albacete, Spain.
Scientific reports
|May 6, 2024
概括
乳腺瘤中的调节性T细胞 (Tregs) 与特定的基因表达相关,预测接受检查点抑制剂治疗的患者的治疗结果更好. 这些发现为免疫反应和癌症治疗提供了新的见解.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 基因组学就是基因组学.
背景情况:
- 调控性T细胞 (Tregs) 是抑制免疫反应的CD4+T细胞.
- 了解高Treg透的瘤的基因组景观对于预测治疗疗效至关重要.
研究的目的:
- 为了确定与乳腺瘤中Treg存在相关的关键转录.
- 探索这些转录与患者预后和对检查点抑制剂的反应的相关性.
主要方法:
- 分析来自乳腺瘤的基因组数据集.
- 转录形状分析以识别与Treg表达相关的基因.
- 与临床结果和免疫治疗反应的相关性分析.
主要成果:
- 四个转录 (BIRC6,MAP3K2,USP4,SMG1) 在乳腺癌亚型中始终与Tregs相关.
- 这些基因的组合预测了有利的结果,并改善了检查点抑制剂的预后.
- 确定了参与细胞膜功能,中性粒细胞激活和巨细胞调节的升调基因,在基底类和HER2+瘤中具有特定的关联.
- 几种基因 (MSR1,CD80,OLR1,ABCA1,TMEM245,ATP13A3) 预测了对抗PD(L) 1和抗CTLA4疗法的反应.
结论:
- 特定的基因特征与乳腺瘤中的Treg存在密切相关.
- 这些基因调节对检查点抑制剂疗法的反应,为治疗选择和结果预测提供潜在的生物标志物.
相关概念视频
Negative Regulator Molecules
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...


